Page last updated: 2024-12-05

chrysarobin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Chrysarobin is a naturally occurring anthraquinone derivative extracted from the wood of the Brazilian rosewood tree ( _Pterocarpus indicus_). It exhibits anti-inflammatory and anti-proliferative properties. It has been traditionally used in dermatology for the treatment of psoriasis, eczema, and other skin conditions. Chrysarobin's mechanism of action involves inhibiting the growth of skin cells and reducing inflammation. Research on chrysarobin focuses on its potential applications in dermatology, including the development of new topical treatments for skin diseases. However, chrysarobin can cause skin irritation and sensitization, limiting its widespread use.'

Cross-References

ID SourceID
PubMed CID10288
CHEMBL ID2135835
SCHEMBL ID5858623
MeSH IDM0062007

Synonyms (31)

Synonym
3-methyl-1,8,9-anthracenetriol
ai3-62089
3-methyl-1,8,9-trihydroxyanthracene
brn 2124735
ccris 5597
1,8,9-trihydroxy-3-methylanthracene
3-methyl-1,8-dihydroxy-9,10-dihydro-9-oxoanthracen
1,8-dihydroxy-3-methylanthron
3-methylanthralin
1,8,9-anthracenetriol, 3-methyl-
chrysophanic acid anthranol
NCGC00181774-01
491-59-8
3-methylanthracene-1,8,9-triol
tox21_113041
dtxcid4028597
cas-491-59-8
dtxsid1048671 ,
purified araroba
unii-0433fjv3ci
4-06-00-07604 (beilstein handbook reference)
0433fjv3ci ,
FT-0632219
purified goa powder
9-hydroxy chrysarobin
NCGC00181774-02
tox21_113041_1
SCHEMBL5858623
chrysophansaureanthranol
CHEMBL2135835
Q27247612

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency33.49150.006038.004119,952.5996AID1159521; AID1159523
GLS proteinHomo sapiens (human)Potency22.38720.35487.935539.8107AID624170
AR proteinHomo sapiens (human)Potency10.68220.000221.22318,912.5098AID743036
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency27.68520.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency4.36490.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency10.68220.000214.376460.0339AID720692
retinoid X nuclear receptor alphaHomo sapiens (human)Potency25.37350.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency20.28120.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency33.48890.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency11.88320.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency17.34500.000229.305416,493.5996AID743075; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency3.09010.01238.964839.8107AID1645842
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency4.82400.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency27.46460.023723.228263.5986AID743223; AID743241
aryl hydrocarbon receptorHomo sapiens (human)Potency4.19590.000723.06741,258.9301AID743085; AID743122
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency33.49150.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency11.23620.000627.21521,122.0200AID743202; AID743219
Interferon betaHomo sapiens (human)Potency3.09010.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency3.09010.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency3.09010.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency3.09010.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (33.33)24.3611
2020's6 (66.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.14 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index69.47 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (78)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Modeling of the Hemoglobin Drop in the Uncomplicated Postoperative Course [NCT03740438]120 participants (Anticipated)Observational [Patient Registry]2018-09-01Recruiting
Pilot Feasibility Study of a Novel Non-invasive Device for Diagnosis of Anemia [NCT06159348]25 participants (Anticipated)Observational2023-12-15Not yet recruiting
A Multi-center, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of MP4OX Treatment, in Addition to Standard Treatment, in Severely Injured Trauma Patients With Lactic Acidosis Due to Hemorrhagic Shock [NCT01262196]Phase 2348 participants (Actual)Interventional2011-05-31Completed
Intradialytic Hypotension in Diabetic Haemodialysis Patients and Its Association With Dialytic Age [NCT03870594]90 participants (Anticipated)Observational2019-04-30Not yet recruiting
HbA1c as an Early Serologic Marker for the Hemodynamic Progression of Stage A Heart [NCT04450576]200 participants (Anticipated)Observational2019-12-20Active, not recruiting
Non-invasive Spot Hemoglobin Measurement in the Outpatient Obstetric Clinic [NCT03175042]40 participants (Actual)Observational2017-06-13Completed
Investigating the Value of Reticulocyte Haemoglobin Content (RET-he) in the Management of Functional Martial Deficiency Anaemia in Patients With Solid Tumours [NCT03656172]54 participants (Actual)Observational [Patient Registry]2017-05-04Completed
Comparison of Two Novel Anti Diabetes Medications Classes as Regard Prostate Symptoms in Patient With Diabetes [NCT06148259]57 participants (Actual)Interventional2021-03-12Completed
A Randomized Controlled Clinical Trial of Transfusion Under the Guidance of West-China Perioperative Transfusion Score(WCPTS)for Massive Hemorrhagic Surgery [NCT01345643]Phase 3120 participants (Anticipated)Interventional2011-02-28Recruiting
Red Cell Distribution Width Index Versus Red Cell Distribution Width as Discriminating Guide for Iron Deficiency Anaemia and Beta Thalassemia Trait . [NCT03868306]100 participants (Anticipated)Observational2019-06-01Not yet recruiting
Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services and Their Impact on Mother and Child Health Outcomes in Cabo Delgado Province, Mozambique [NCT02191527]1,673 participants (Actual)Interventional2013-09-30Completed
Estimated Blood Loss: Novel Model for Estimating Surgical Blood Loss. [NCT03249038]100 participants (Actual)Observational2017-01-01Completed
Dietary Diversity of Young Children During CoVID-19 Outbreak: A Longitudinal Study [NCT04447209]469 participants (Actual)Observational2020-06-06Completed
Non-Invasive Estimation of Hemoglobin Levels in Blood Using Combined Deep Learning Methods [NCT04865224]353 participants (Actual)Observational2020-07-15Completed
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock. Diagnosis and Monitoring of Treatment Based on Standard and New Laboratory Parameters. [NCT05217836]90 participants (Anticipated)Observational2021-09-24Recruiting
The Association of the Levels of Blood Haemoglobin to the Distribution and Severity of Gingival Melanin Pigmentation at 3 Different Periodontal Health Status [NCT03791957]60 participants (Anticipated)Observational [Patient Registry]2019-12-20Not yet recruiting
A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer [NCT03568630]1,250 participants (Anticipated)Observational2018-07-26Recruiting
Hematological Factors and Iron Status in Aerobic Versus Anaerobic Training in Athletic Females: An Observational Study [NCT05707455]25 participants (Actual)Observational2022-09-01Completed
Anthropometric Measurements in Children Having Transfusion-dependent Beta Thalassemia. [NCT03947632]367 participants (Actual)Observational [Patient Registry]2013-01-01Completed
Early Investigation of Glucose Monitoring After Gestational Diabetes (ENGAGED): Utility and Acceptability of Continuous Glucose Monitoring in the Early Postpartum Period After Gestational Diabetes Mellitus [NCT06184373]20 participants (Anticipated)Observational2024-01-01Not yet recruiting
A Novel Device for Surveillance of Vascular Access Sites for Bleeding [NCT04285775]250 participants (Actual)Observational2019-03-01Completed
Abdominal Ultrasound Assessment in the Post-cesarean Patient [NCT02159105]105 participants (Actual)Observational2014-06-30Completed
Non-invasive Continuous Total Hemoglobin Measurement by Pulse CO-Oximetry in Major Spine Surgery [NCT04506957]50 participants (Anticipated)Observational [Patient Registry]2020-12-01Not yet recruiting
The Effect of Glycemic Control on Visual and Anatomical Outcomes in Response to Therapy for Diabetic Macular Edema. [NCT01358396]52 participants (Actual)Observational2010-01-31Completed
Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control [NCT06067399]250 participants (Anticipated)Observational2023-12-25Not yet recruiting
A Comparison Between Two Strategies for Postpartum Anemia Diagnosis and Follow up After Vaginal Deliveries - Hemoglobin Screening in High Risk Population Versus by Symptoms [NCT02434653]1,679 participants (Actual)Interventional2015-06-30Completed
NIRS: a Tool for the Diagnosis and Prevention of Acute Renal Failure in Pediatric Cardiac Surgery [NCT04605705]100 participants (Anticipated)Observational2020-09-23Recruiting
Establishment of Optimal Transfusion Threshold After Major Orthopedic Surgery [NCT00906295]67 participants (Actual)Interventional2009-06-30Completed
Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study [NCT02650388]Phase 4100 participants (Anticipated)Interventional2015-11-30Recruiting
Post-operative Anemia in Lateral Fragility Fractures of the Femur. A Prospective Observational Study in Three Different Intramedullary Nails [NCT05225753]45 participants (Actual)Observational2020-11-01Completed
Levonorgestrel Intrauterine System Effects on Hemoglobin and Serum Ferritin Among Anemic Women in Kenya: an Open Label Randomized Trial to Compare With an Oral Contraceptive Regimen That Provides Supplemental Ferrous Fumarate Tablets [NCT05233956]600 participants (Anticipated)Interventional2023-10-23Recruiting
Establishment of Optimal Transfusion Threshold During Spine Surgery [NCT00967109]60 participants (Anticipated)Interventional2009-09-30Completed
Accuracy of the Noninvasive Radical-7 Pulse Co-oximeter at Detecting Hemoglobin Changes in Pediatric Cardiac Intensive Care [NCT03977142]25 participants (Anticipated)Observational2019-08-31Not yet recruiting
Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus [NCT00898534]Phase 4234 participants (Actual)Interventional2003-11-30Completed
Comparison of the Hemoglobin Results Obtained With the Masimo SpHb™ Device and the Clinical Laboratory Measurement [NCT00912379]300 participants (Actual)Observational2009-06-30Completed
The Benefit of the Blood Glucose Self Monitoring and a Regular Three-monthly Hemoglobin A1c Profile in Patients With Type 2-diabetes and Conventional Insulin Therapy [NCT00688363]Phase 4300 participants (Actual)Interventional2003-02-28Completed
Evaluation of the Accuracy and Precision of the Masimo Labs Pulse-Hemoglobin-Meter Monitor in Surgical Patients [NCT00762398]40 participants (Actual)Observational2008-09-30Terminated
Integrated Studies in Vascular Reactivity and Anemia Correction Therapy in Endstage Kidney Disease Patients [NCT00175734]80 participants (Anticipated)Interventional2005-08-31Active, not recruiting
Liver Resection and Non-invasive Measurement of Hemoglobin Concentration With Pulse Co-oximetry [NCT01060683]30 participants (Actual)Observational2010-01-31Completed
Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial [NCT01839864]0 participants (Actual)Interventional2013-09-30Withdrawn(stopped due to Funding for the study was not received. No recruitment ever occurred.)
A Multi-center, Multinational, Randomized, Double-blind, Controlled, Dose Comparison Study to Evaluate Safety and Efficacy of MP4OX Plus Standard Treatment, in Severely Injured Trauma Subjects With Lactic Acidosis Due to Hemorrhagic Shock [NCT01973504]Phase 20 participants (Actual)Interventional2013-12-31Withdrawn(stopped due to Sangart ceased operations)
Liberal Versus Restrictive Transfusion Threshold in High-risk Oncologic surgerY: a Multicenter, Randomized, Controlled, Pilot Study [NCT04506125]30 participants (Actual)Interventional2021-03-18Completed
A Cross- Sectional Study on the Prevalence of Malaysian Children Aged ≥ 6 to ≤ 36 Months at Risk of Anaemia [NCT05181436]1,215 participants (Actual)Observational2022-07-19Active, not recruiting
Noninvasive and Continuous Hemoglobin Monitoring for Surgical Blood Management [NCT01686659]470 participants (Anticipated)Interventional2012-09-30Recruiting
Comparison of Alternative Non-invasive and Invasive Methods of Haemoglobin Measuring With the Gold Standard in Preterm and Term Neonates [NCT02722759]41 participants (Actual)Interventional2016-03-31Completed
Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus [NCT04216303]0 participants (Actual)Observational2019-09-12Withdrawn(stopped due to PI decided to stop the study)
Phase II, Open-Label Study in the Catheterization Laboratory Setting to Challenge the Concept That HBOC-201 Administration Might Improve Myocardial 'Oxygenation' and Myocardial Function at the Moment of (Brief) Coronary Occlusion [NCT00479895]Phase 25 participants (Actual)Interventional2007-04-30Completed
[NCT03124758]354 participants (Actual)Interventional2010-04-20Completed
Phase II, Multi-Center,Single-Blind,Placebo-Controlled Study,Evaluating Safety & Feasibility of HBOC-201 (Wound Healing Patients With Peripheral Vascular Disease & Undergoing Lower Limb Amputation Due to Critical Lower Limb Ischemia [NCT00300040]Phase 216 participants (Actual)Interventional2006-05-31Terminated(stopped due to Very slow enrollment.Study entry criteria not in line w/local standards of care)
A Single-Center, Study to Evaluate the Safety and Tolerability of Hemoglobin-Based Oxygen Carrier-201 (HBOC 201) in Trauma Subjects. (Phase II - Safety and Tolerability) [NCT00301483]Phase 253 participants (Anticipated)Interventional2004-07-31Recruiting
Chronic Kidney Disease and Cardiovascular Disease Risk Assessment in Yakima County [NCT03975439]0 participants (Actual)Observational2020-02-01Withdrawn(stopped due to Decided to do smaller pilot study instead)
A Multi-Center,Randomized,Double-Blind,Placebo-Controlled,Dose Finding Pilot Study, to Evaluate Safety/Feasibility of HBOC-201 in Elective Percutaneous Coronary Revascularization of Subjects With Acute Coronary Syndromes [NCT00317512]Phase 245 participants (Actual)Interventional2003-12-31Completed
Comparison of Three Methods of Hemoglobin Monitoring in Patients Undergoing Spine or Hip Surgery [NCT01284296]20 participants (Actual)Interventional2010-08-31Completed
Integrated Studies in Vascular Reactivity and Anaemia Correction Therapy in Endstage Kidney Disease Patients [NCT00226902]15 participants Interventional2006-09-30Completed
A Phase 3, Multi-Center, Randomized, Placebo Controlled Study of PHP When Administered by Continuous Infusion in Patients With Shock Associated With Systemic Inflammatory Response Syndrome (SIRS) [NCT00021502]Phase 31,000 participants Interventional2001-03-31Completed
A Phase II, Randomized, Single-Blind, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Hemolink[Tm] (o-Raffinose Cross-Linked Human Hemoglobin) in Subjects Undergoing Primary Coronary Artery Bypass Grafting Surgery [NCT00038454]Phase 2/Phase 3180 participants InterventionalSuspended
Continuous and Noninvasive Hemoglobin Monitoring Reduces Red Blood Cell Transfusion During Neurosurgery: A Prospective Cohort Study [NCT01906515]106 participants (Actual)Interventional2012-02-29Completed
Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels (110- 129 g/L and 130 - 149 g/L) on Progression of Chronic Kidney Disease in Patients With Type 2 Diabetes and With Chronic Kidney Disease [NCT00279084]204 participants Interventional2004-01-31Active, not recruiting
Enhancement of Tissue Preservation During Cardiopulmonary Bypass With HBOC-201 (Registry Study) [NCT00301535]Phase 260 participants (Anticipated)Interventional2006-02-28Recruiting
Influence of the Inspired Oxygen Fraction on the Noninvasive Measurement of Hemoglobin Using Two Different Devices (Namely Pronto 7 and NBM-200) [NCT01654913]47 participants (Actual)Interventional2012-07-31Completed
1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin Ratio as a Potential Biomarker for Islet β-cell Function and Insulin Resistance Among Patients With Type 2 Diabetes Mellitus [NCT04869605]90 participants (Anticipated)Observational [Patient Registry]2021-05-06Recruiting
Verifying the Accuracy of the Masimo Pronto Non-Invasive Hemoglobin (Hb) Monitor and Associated Rainbow Probes Compared to Measured Laboratory Values in Critically Ill Pediatric Patients [NCT01750463]65 participants (Actual)Observational2013-01-31Completed
Comparative Effectiveness of Point-of-care Glycosylated Hemoglobin Measurement (POC-A1c) vs the Current Standard Based on Oral Glucose Tolerance Test for Early Detection of Type 2 Diabetes Mellitus (DM2) in Colombia [NCT05440968]902 participants (Actual)Interventional2022-06-30Active, not recruiting
Blood Loss Quantification During Major Abdominal Surgery: Study Protocol for a Prospective Cohort Trial. [NCT05316649]45 participants (Anticipated)Observational2021-05-01Recruiting
Investigating the Association of Shock Index and Hemoglobin Variation With Postpartum Hemorrhage After Vaginal Deliveries: A Prospective Cohort Study [NCT03432767]67 participants (Actual)Observational2016-02-16Completed
Volume Kinetics for Starch Solution and Acetated Ringers [NCT01195025]10 participants (Actual)Interventional2010-08-31Completed
Effect of West China Perioperative Transfusion Score (WCPTS) on Red Blood Cells Transfusion in Patients Undergoing Major Surgery: a Prospective, Multicenter, Randomized Controlled Trial [NCT01597232]1,351 participants (Actual)Interventional2012-05-07Completed
Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects [NCT00001963]Phase 128 participants Interventional1999-12-31Completed
Outcomes of Diabetes In Hospitalized COVID-19 Patients At Assiut University Hospital [NCT05083013]160 participants (Anticipated)Observational2021-11-01Not yet recruiting
Use of Reticulocyte Ratio and Neutrophil / Lymphocyte Ratio in the Diagnosis of Ventilator-associated Pneumonia [NCT04620941]35 participants (Anticipated)Observational [Patient Registry]2020-02-21Suspended(stopped due to Due to the covid pandemic, I was only assigned to the covid intensive care unit.)
Investigation of the Effects of Topical Haemoglobin Wound Care Spray in Pressure Ulcer Care [NCT05915169]18 participants (Anticipated)Interventional2023-09-30Not yet recruiting
A Multi-center, Single Blinded Randomized Trial Investigating Indications Based Blood Transfusion Practices in Patients With Major Oncological Surgery [NCT05607940]Phase 2/Phase 3260 participants (Anticipated)Interventional2023-01-31Not yet recruiting
Comparison of Masimo Total Hemoglobin SpHb® Continuous Non-invasive Hemoglobin Monitoring Device With Laboratory Complete Blood Count Measurement Using Venous Sample: A Substudy of the Pregnancy Risk Stratification Innovation and Measurement Alliance Mate [NCT05656352]2,700 participants (Anticipated)Observational2022-09-22Recruiting
The Perioperative Liberal or Restrictive Transfusion in Pediatric Liver Transplantation: A Prospective Randomized Controlled Trial [NCT02951013]488 participants (Anticipated)Interventional2016-12-07Recruiting
The Effect of Non-invasive Hemoglobin Measurement on Blood Transfusion and Mortality in Hip Surgeries: a Randomized Controlled Trial [NCT04785274]40 participants (Actual)Observational2021-01-01Completed
Validation of Hb-measurement of Pronto ® as Screening Tool for Preoperative Diagnostic of Anemia [NCT03586141]1,129 participants (Actual)Interventional2018-07-22Completed
CLIA Waived Study: StatStrip Lactate, Hemoglobin, and Hematocrit Meter in Whole Blood [NCT05118048]285 participants (Actual)Observational2021-01-18Terminated(stopped due to Patient recruitment too slowly)
Can Point-of-care Testing (POCT) and Assistance From Comprehensive Medication Management (CMM) Pharmacists Improve Early Detection and Management of Metabolic Syndrome in Patients Treated With Antipsychotic Medications? [NCT02029989]121 participants (Actual)Interventional2010-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01195025 (4) [back to overview]Accuracy of Non-invasive Hemoglobin Monitoring for Different Fluids
NCT01195025 (4) [back to overview]Accuracy of Noninvasive Haemoglobin Measurement by Pulse Oximetry, for Different Fluids (Start to End of Infusion)
NCT01195025 (4) [back to overview]Elimination Half Life for Different Fluids Alone or When Combined
NCT01195025 (4) [back to overview]Volume Effects for Hydroxyethyl Starch, Ringer's Solution or a Combination of Both.
NCT01284296 (1) [back to overview]Categorical Groups Based on Magnitude of Differences Between Noninvasive (SpHb) and Laboratory Co-Oximeter (tHb) Hemoglobin in Patients With a Finger Regional Anesthetic Block.
NCT01906515 (2) [back to overview]RBC Transfusions Per Subject Receiving a Transfusion
NCT01906515 (2) [back to overview]The Effect of SpHb on Transfusion Timeline
NCT02029989 (1) [back to overview]Metabolic Syndrome (MetS)
NCT03124758 (1) [back to overview]Accuracy of Sensor by Arms Calculation

Accuracy of Non-invasive Hemoglobin Monitoring for Different Fluids

"Pulse-oximeter based measurements compared with invasive hemoglobin measurements. All paired in the study.~Accuracy depending on which infusion is selected (Ringer's, Hydroxyethyl starch or a combination of both)." (NCT01195025)
Timeframe: 420 min

Interventionpercentage of relative difference (Median)
Ringers acetateHES 6%HES 6% + Ringers acetate
Venous Hemoglobin and Non-invasive Hemoglobin (SpHb)-5.30.01.5

[back to top]

Accuracy of Noninvasive Haemoglobin Measurement by Pulse Oximetry, for Different Fluids (Start to End of Infusion)

"Difference between true hemoglobin B-Hb and measured hemoglobin with pulseoximeter (SpHb)at the end of an infusion in relation to the initial measured values SpHb and B-Hb at the start of the infusion.~Relative difference (%) = (SpHb - Hb)/((Hb+SpHb)/2) x 100" (NCT01195025)
Timeframe: 30 min

Interventionpercentage of relative difference (Median)
Ringer's acetateHydroxy ethyl starch 6%
Colloid (Voluven), Acetated Ringers and a Combination of Both.7-4.3

[back to top]

Elimination Half Life for Different Fluids Alone or When Combined

Volume kinetic analyses of the dilution of hemoglobin for different infusion fluids alone or in combination. (NCT01195025)
Timeframe: 420 minutes

InterventionMinutes (Median)
Elimination half life for Ringer'sElimination half life for HESElimination half life for HES (+ Ringer's)Elimination half life for Ringer's (+ HES)
Hydroxyethyl Starch, Ringers and a Combination of Both.88116126497

[back to top]

Volume Effects for Hydroxyethyl Starch, Ringer's Solution or a Combination of Both.

"volume kinetics: mathematical calculation from hemoglobin variations during and after an infusion.~Degree of plasma dilution depending on which solution(s) and how much solution is/are given." (NCT01195025)
Timeframe: 420 minutes

InterventionLitre (Median)
Distribution volume of Acetated RingersDistribution volume for HES 6%Distribution vol for HES combined with Ringer'sDistribution vol for Ringers combined with HES
Hydroxyethyl Starch, Ringers and a Combination of Both.5.532.943.124

[back to top]

Categorical Groups Based on Magnitude of Differences Between Noninvasive (SpHb) and Laboratory Co-Oximeter (tHb) Hemoglobin in Patients With a Finger Regional Anesthetic Block.

(NCT01284296)
Timeframe: A minimum of 2-4 differences recorded approximately hourly during surgery

,
Interventionpercentage of hemoglobin readings (Number)
< 0.5 g/dL0.5-1.0 g/dL1.1-1.5 g/dL1.6-2.0 g/dL>2.0 g/dL
Digital Block (All Perfusion Indices 0.29-8.3)371918179
Digital Block (Perfusion Indices >2.0)372620143

[back to top]

RBC Transfusions Per Subject Receiving a Transfusion

Determine whether using SpHb can affect the quantity of RBC transfused, per patient receiving a transfusion. (NCT01906515)
Timeframe: During surgery (an average of about 4 hours)

Interventionunits (Mean)
SpHb Group.2.3
Control Group3.9

[back to top]

The Effect of SpHb on Transfusion Timeline

Length of time it takes to initiate a RBC transfusion after the need was first established. (NCT01906515)
Timeframe: During surgery (an average of about 4 hours)

Interventionminutes (Mean)
SpHb Group.9.2
Control Group50.2

[back to top]

Metabolic Syndrome (MetS)

compare test results in subjects between the PCS and NCS groups, with or without pre-existing MetS and/or related metabolic conditions at baseline (NCT02029989)
Timeframe: Baseline

Interventionpercentage of participants (Number)
Pharmacist Comprehensive Medication Management Service (PCS)85.2
No Comprehensive Medication Management Services (NCS)71.2

[back to top]

Accuracy of Sensor by Arms Calculation

Accuracy will be determined by comparing the noninvasive hemoglobin measurement of the pulse oximeter to the hemoglobin value obtained from a blood sample and calculating the arithmetic root mean square(Arms) error value. (NCT03124758)
Timeframe: 1-5 hours

Interventiong/dL (Number)
Noninvasive Hemoglobin Sensor1.0

[back to top]